ethyl 4-oxocycloheptanecarboxylate | 171361-62-9

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: ethyl 4-oxocycloheptanecarboxylate
• 英文别名: Ethyl 4-oxocycloheptane-1-carboxylate；ethyl 4-oxocycloheptane-1-carboxylate
• CAS: 171361-62-9
• 化学式: C₁₀H₁₆O₃
• 分子量: 184.235
• InChiKey: NJVZJSGXOCJBIO-UHFFFAOYSA-N

物化性质

• 沸点：
  268.7±33.0 °C(Predicted)
• 密度：
  1.053±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  43.4
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  ethyl 4-oxocycloheptanecarboxylate 在 二乙胺基三氟化硫 作用下， 以 二氯甲烷 为溶剂， 反应 72.0h， 以63%的产率得到ethyl 4,4-difluorocycloheptanecarboxylate
  参考文献：
  名称：

  最后的宝石二氟环烷烃 2：氟化环庚烷结构单元的合成

  摘要：

  通过两到六个合成步骤，从容易获得的起始材料中获得了一系列异构的偕-二氟环庚烷衍生物。已开发的合成方法被证明对于目标化合物的多克级合成是有效的，并且涉及六元环同系化和/或脱氧氟化反应作为关键步骤。

  DOI：

  10.1002/ejoc.202001530
• 作为产物：
  描述：

  对环己酮甲酸乙酯 在 正丁基锂 、 silica gel 、 sodium sulfate 作用下， 以 四氢呋喃 、 乙醚 、 正己烷 为溶剂， 反应 1.17h， 生成 ethyl 4-oxocycloheptanecarboxylate
  参考文献：
  名称：

  环酮的亚甲基同构新方法

  摘要：

  向一只老狗教新的花样：通过截获酮与三甲基硅烷基重氮甲烷锂之间的加合物，可以通过一步操作实现新的Tiffeneau–Demjanov型亚甲基同系物。在质子源和路易斯酸中，发现硅胶是中间体中间体的质子化和随后环扩环的最有效试剂（请参见方案）。

  DOI：

  10.1002/chem.201201346

文献信息

• An Unconventional Redox Cross Claisen Condensation–Aromatization of 4-Hydroxyprolines with Ketones
  作者：Mi Tang、Rengwei Sun、Hao Li、Xinhong Yu、Wei Wang

  DOI：10.1021/acs.joc.7b01033

  日期：2017.8.18

  Reaction of α-amino acids, particularly prolines and their derivatives with carbonyl compounds via decarboxylative redox process, is a viable strategy for synthesis of structurally diverse nitrogen centered heterocyclics. In these processes, the decarboxylation is the essential driving force for the processes. The realization of the redox process without decarboxylation may offer an opportunity to

  α-氨基酸，特别是脯氨酸及其衍生物通过脱羧氧化还原过程与羰基化合物的反应，是合成结构多样的以氮为中心的杂环的可行策略。在这些方法中，脱羧是该方法的基本驱动力。没有脱羧的氧化还原过程的实现可能提供探索新反应的机会。在本文中，我们报道了4取代的4-羟基脯氨酸及其酯与未反应的酮发生前所未有的氧化还原Claisen型缩合芳构化级联反应的发现。我们发现使用丙酸作为催化剂和助溶剂可以改变反应过程。通常观察到的氧化还原脱羧和醛醇缩合反应显着最小化。而且，非反应性酮可有效参与克莱森缩合反应。新的反应性通过非常规的Claisen型缩合反应使氧化还原环化成为可能。由酮前体与4-取代的4-羟基脯氨酸及其酯作为亲电子酰化伙伴原位形成烯胺中间体。在反应条件下，级联反应可进行高度区域选择性和立体选择性，从而获得具有高合成和生物学价值的顺式-2,3-二氢-1 H-吡咯烷酮-1-酮，在有效的“一锅法”操作中具有广泛的底物范围，而此类结构通常需要多个步骤。
• Synthesis of 3- and 4-substituted cyclic α-amino acids structurally related to ACPD
  作者：Francisco Alonso、Irene Micó、Carmen Nájera、José M. Sansano、Miguel Yus、Jesús Ezquerra、Belén Yruretagoyena、Ismael Gracia

  DOI：10.1016/0040-4020(95)00586-w

  日期：1995.9

  The preparation of 3-substituted cyclopentanones 12-16, 4-substituted cyclohexanones 23–28 and cycloheptanones 38–41 is described. Substituents in the cycloalkanones are carboxylate, phosphonate or tetrazole groups, separated from the ring by a 0, 1, 2, or 3 carbon atoms chain. These cycloalkanones have been transformed into α-amino acids 9–11 by hydrolysis of the corresponding hydantoin derivatives

  的3-取代的环戊酮的制备12-16，4-取代的环己酮23-28和cycloheptanones 38-41进行说明。环烷酮中的取代基是羧酸酯基，膦酸酯基或四唑基，它们通过0、1、2或3个碳原子链与环隔开。这些环烷酮已变成α氨基酸9-11由相应的乙内酰脲衍生物的水解21，37和62，Bucherer-Bergs反应条件下获得。
• [EN] NOVEL TRICYCLIC COMPOUNDS AS INHIBITORS OF MUTANT IDH ENZYMES<br/>[FR] NOUVEAUX COMPOSÉS TRICYCLIQUES UTILISÉS EN TANT QU'INHIBITEURS D'ENZYMES IDH MUTANTES
  申请人：MERCK SHARP & DOHME

  公开号：WO2016089830A1

  公开（公告）日：2016-06-09

  The present invention is directed to tricyclic compounds of formula (I) which are inhibitors of one or more mutant IDH enzymes (I); wherein A is -C(R1)= or -N=; and X is selected from the group consisting of: (II-i), and (II-ii). The present invention is also directed to uses of the tricyclic compounds described herein in the potential treatment or prevention of cancers in which one or more mutant IDH enzymes are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such cancers.

  本发明涉及式(I)的三环化合物，其为一种或多种突变IDH酶的抑制剂；其中A为-C(R1)=或-N=；X从以下组中选择：(II-i)和(II-ii)。本发明还涉及所述三环化合物在潜在治疗或预防涉及一种或多种突变IDH酶的癌症中的用途。本发明还涉及包含这些化合物的组合物。本发明还涉及这些组合物在潜在预防或治疗此类癌症中的用途。
• [EN] NOVEL TRICYCLIC COMPOUNDS AS INHIBITORS OF MUTANT IDH ENZYMES<br/>[FR] NOUVEAUX COMPOSÉS TRICYCLIQUES COMME INHIBITEURS D'ENZYMES IDH MUTANTES
  申请人：MERCK SHARP & DOHME

  公开号：WO2016089833A1

  公开（公告）日：2016-06-09

  The present invention is directed to tricyclic compounds of formula (I) which are inhibitors of one or more mutant IDH enzymes: (I); wherein A is -C(R1)= or -N=; and X is selected from the group consisting of: (II-i), (II-ii), (II-iii), and (II-iv). The present invention is also directed to uses of the tricyclic compounds described herein in the potential treatment or prevention of cancers in which one or more mutant IDH enzymes are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such cancers.

  本发明涉及式(I)的三环化合物，这些化合物是一种或多种突变IDH酶的抑制剂：(I)；其中A为-C(R1)=或-N=；X选自以下组中的一种：(II-i)、(II-ii)、(II-iii)和(II-iv)。本发明还涉及所述三环化合物在潜在治疗或预防涉及一种或多种突变IDH酶的癌症中的用途。本发明还涉及包含这些化合物的组合物。本发明还涉及这些组合物在潜在预防或治疗此类癌症中的用途。
• Tricyclic compounds as inhibitors of mutant IDH enzymes
  申请人：Merck Sharp & Dohme Corp.

  公开号：US10086000B2

  公开（公告）日：2018-10-02

  The present invention is directed to tricyclic compounds of formula (I) which are inhibitors of one or more mutant IDH enzymes: (I); wherein A is —C(R1)= or —N═; and X is selected from the group consisting of: (II-i), (II-ii), (I) (II-iii), and (II-iv). The present invention is also directed to uses of the tricyclic compounds described herein in the potential treatment or prevention of cancers in which one or more mutant IDH enzymes are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such cancers.

  本发明涉及式(I)的三环化合物，它是一种或多种突变IDH酶的抑制剂：(I)；其中A是-C(R1)＝或-N═；X选自由(II-i)、(II-ii)、(I)(II-iii)和(II-iv)组成的组。本发明还涉及本文所述三环化合物在潜在治疗或预防涉及一种或多种突变 IDH 酶的癌症中的用途。本发明还涉及包含这些化合物的组合物。本发明还涉及这些组合物在潜在预防或治疗此类癌症中的用途。